Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280903 | 0.90 | TSHR (0.47) | CHEK1 | |
| SCHEMBL2836782 | 0.80 | PDE3B (0.61) | PDE3BPDE3A | |
| SCHEMBL6031474 | 0.73 | EGFR (0.50) | PDE3BPDE3A | |
| SCHEMBL6487209 | 0.72 | TSHR (0.47) | — | |
| SCHEMBL15613194 | 0.70 | EGFR (0.46) | CHEK1 | |
| SCHEMBL5912839 | 0.70 | MAPT (0.50) | PDE3BPDE3A | |
| SCHEMBL6881241 | 0.70 | CHEK1 (0.42) | CHEK1TLR7TLR9EHMT2EHMT1 | |
| SCHEMBL4025116 | 0.70 | EHMT2 (0.52) | CHEK1DRD2DRD3TLR7TLR9 | |
| SCHEMBL12448364 | 0.68 | KDM4E (0.51) | DRD2DRD3EHMT2EHMT1 | |
| SCHEMBL4096057 | 0.68 | EGFR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | PDE3B 730/4885PDE3A 376/4885CHEK1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.